CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Senexin C
CAS:<p>Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.</p>Formula:C28H27N5OPurity:98.06%Color and Shape:SolidMolecular weight:449.55Bisindolylmaleimide X hydrochloride
CAS:<p>Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).</p>Formula:C26H25ClN4O2Purity:99.23%Color and Shape:SolidMolecular weight:460.96Cdc7-IN-7
CAS:<p>Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.</p>Formula:C21H22N4O5Purity:98.78%Color and Shape:SolidMolecular weight:410.42CDK9-IN-23
CAS:<p>CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].</p>Formula:C22H25ClN4O3Purity:98%Color and Shape:SolidMolecular weight:428.91Senexin A hydrochloride
CAS:<p>Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].</p>Formula:C17H15ClN4Color and Shape:SolidMolecular weight:310.78CDK9-IN-19
CAS:<p>CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.</p>Formula:C26H22F2N4O5Color and Shape:SolidMolecular weight:508.47Riviciclib
CAS:<p>Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.</p>Formula:C21H20ClNO5Purity:98%Color and Shape:SolidMolecular weight:401.84ML 315 hydrochloride
CAS:<p>ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].</p>Formula:C18H14Cl3N3O2Color and Shape:SolidMolecular weight:410.682(S)-Cdc7-IN-18
CAS:<p>'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'</p>Formula:C19H21N5OSColor and Shape:SolidMolecular weight:367.47CDK7-IN-25
CAS:<p>CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].</p>Formula:C33H32N6O3Purity:98%Color and Shape:SolidMolecular weight:560.65Inixaciclib
CAS:<p>Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.</p>Formula:C26H30F2N6OColor and Shape:SolidMolecular weight:480.55SZ-015268
CAS:<p>SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.</p>Formula:C25H38N8O3Color and Shape:SolidMolecular weight:498.62CDK4/6-IN-15
CAS:<p>CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.</p>Formula:C21H27FN8SColor and Shape:SolidMolecular weight:442.56CDK4/6-IN-17
CAS:<p>CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.</p>Formula:C27H28F4N8Purity:98%Color and Shape:SolidMolecular weight:540.56Cdc7-IN-12
CAS:<p>Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).</p>Formula:C16H14N2O2SColor and Shape:SolidMolecular weight:298.36Xylocydine
CAS:<p>Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.</p>Formula:C12H14BrN5O5Color and Shape:SolidMolecular weight:388.17CF53
CAS:<p>CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.</p>Formula:C24H25N7O2Purity:99.72%Color and Shape:SolidMolecular weight:443.5Cdk1/2 Inhibitor III
CAS:<p>Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.</p>Formula:C15H13F2N7O2S2Purity:99.07%Color and Shape:SolidMolecular weight:425.44(R)-Simurosertib
CAS:<p>(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.</p>Formula:C17H19N5OSPurity:99.89%Color and Shape:SolidMolecular weight:341.43XY028-140
CAS:<p>XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.</p>Formula:C39H40N10O7Purity:98.59%Color and Shape:SolidMolecular weight:760.8Debio-0123
CAS:<p>Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.</p>Formula:C26H28Cl2N6OPurity:99.93%Color and Shape:SolidMolecular weight:511.45AZD4573
CAS:<p>AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.</p>Formula:C22H28ClN5O2Purity:99% - 99.51%Color and Shape:SolidMolecular weight:429.94PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Formula:C25H27N7Color and Shape:SolidMolecular weight:425.53CDK1-IN-7
CAS:<p>CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.</p>Formula:C23H19ClN4O3Color and Shape:SolidMolecular weight:434.88YL-1-9
CAS:<p>YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].</p>Formula:C22H23F3N2O3Color and Shape:SolidMolecular weight:420.425CDK9 autophagic degrader 1
CAS:<p>CDK9 autophagic degrader 1 (Compound 28) is an ATTEC degrader used to target and degrade CDK9, also impacting the levels of its associated Cyclin T1. At a concentration of 100 nM, it exhibits over 80% inhibition of CDK9.</p>Formula:C34H39N7O4S2Color and Shape:SolidMolecular weight:673.848CDK9-IN-11
CAS:<p>CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].</p>Formula:C20H25N3O4Purity:98%Color and Shape:SolidMolecular weight:371.43RGB-286638
CAS:<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Formula:C29H37Cl2N7O4Color and Shape:SolidMolecular weight:618.55Cimpuciclib tosylate
CAS:<p>Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.</p>Formula:C37H43FN8O4SColor and Shape:SolidMolecular weight:714.85CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Formula:C18H20F3N7O3S2Color and Shape:SolidMolecular weight:503.52CDK2 degrader 4
CAS:<p>CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.</p>Formula:C23H26ClN3O5Color and Shape:SolidMolecular weight:459.923CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Color and Shape:SolidPROTAC CDK12/13 Degrader-1
<p>PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.</p>Color and Shape:SolidCDK7-IN-33
CAS:<p>CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.</p>Formula:C29H36N6O4SColor and Shape:SolidMolecular weight:564.699CDK/HDAC-IN-1
<p>CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.</p>Formula:C20H18N4O4Color and Shape:SolidMolecular weight:378.38LZ9
CAS:<p>LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.</p>Formula:C17H11F3N4O2Color and Shape:SolidMolecular weight:360.29CDK1-IN-3
<p>CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.</p>Formula:C28H25ClF3N5O2Color and Shape:SolidMolecular weight:555.98Haspin-IN-2
CAS:<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Formula:C12H8N4O3Color and Shape:SolidMolecular weight:256.22CDK4-IN-1
CAS:<p>CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50</p>Formula:C22H29ClN8Purity:98%Color and Shape:SolidMolecular weight:440.97Cdc7-IN-10
CAS:<p>Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.</p>Formula:C20H22F2N4O2SColor and Shape:SolidMolecular weight:420.48DDO-6079
CAS:<p>DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.</p>Formula:C18H13ClN2O3Color and Shape:SolidMolecular weight:340.76CDK7-IN-18
CAS:<p>CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.</p>Formula:C22H24F3N7OSColor and Shape:SolidMolecular weight:491.53CLK1/2-IN-1
CAS:<p>CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.</p>Formula:C21H20F3N7OPurity:98%Color and Shape:SolidMolecular weight:443.42TMX-3013
CAS:<p>TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.</p>Formula:C17H14BrFN6O3SColor and Shape:SolidMolecular weight:481.3CDK2-IN-8
<p>CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.</p>Formula:C22H25N5O3Color and Shape:SolidMolecular weight:407.47CDK2-IN-31
CAS:<p>CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.</p>Formula:C37H52N6O5Color and Shape:SolidMolecular weight:660.85CDK12/13 ligand 1
CAS:<p>ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.</p>Formula:C26H26BrN5OColor and Shape:SolidMolecular weight:504.42CDK1-IN-5
<p>CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.</p>Formula:C27H26ClN5OSColor and Shape:SolidMolecular weight:504.05CDK5-IN-2
CAS:<p>CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).</p>Formula:C29H28FN5OColor and Shape:SolidMolecular weight:481.56CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Formula:C18H13N3O2Color and Shape:SolidMolecular weight:303.31GSK3-IN-10
CAS:<p>GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.</p>Formula:C17H18F2N4O3Color and Shape:SolidMolecular weight:364.347DB18
CAS:<p>DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].</p>Formula:C24H18ClN7O3Color and Shape:SolidMolecular weight:487.9(R)-Atuveciclib
CAS:<p>Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].</p>Formula:C18H18FN5O2SPurity:98%Color and Shape:SolidMolecular weight:387.43CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Formula:C21H23N7O2SColor and Shape:SolidMolecular weight:437.52CDK2 degrader 6
CAS:<p>CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.</p>Formula:C23H22F5N5O3Color and Shape:SolidMolecular weight:511.44INX-315
CAS:<p>INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.</p>Formula:C19H21N7O3SPurity:99.88%Color and Shape:SolidMolecular weight:427.48CDK9-IN-13
<p>CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.</p>Formula:C27H35N5O2Color and Shape:SolidMolecular weight:461.6CDK8-IN-11 hydrochloride
<p>CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.</p>Formula:C19H16ClF3N4O2Color and Shape:SolidMolecular weight:424.8CDK9-IN-38
CAS:<p>CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.</p>Formula:C22H23N5O3SColor and Shape:SolidMolecular weight:437.515CDK4/6-IN-13
CAS:<p>Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.</p>Formula:C25H29N7OColor and Shape:SolidMolecular weight:443.54CLK1/4-IN-1
<p>CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.</p>Formula:C18H14ClNO4SColor and Shape:SolidMolecular weight:375.83Anticancer agent 29
<p>Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).</p>Formula:C22H15ClFNOColor and Shape:SolidMolecular weight:363.81CDK4/6-IN-24
CAS:<p>CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.</p>Formula:C32H41N7O3Color and Shape:SolidMolecular weight:571.713Zeltociclib
CAS:<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Formula:C18H20F3N4O2PColor and Shape:SolidMolecular weight:412.346Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Formula:C19H21N5OSColor and Shape:SolidMolecular weight:367.47Cdc7-IN-11
CAS:<p>Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.</p>Formula:C20H22F2N4O2SColor and Shape:SolidMolecular weight:420.48CDK2-IN-40
CAS:<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Formula:C16H21N7O2Color and Shape:SolidMolecular weight:343.384CDK2-IN-30
CAS:<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>Formula:C18H25N7O3SColor and Shape:SolidMolecular weight:419.50CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Formula:C21H22N4OColor and Shape:SolidMolecular weight:346.43CDDD11-8
CAS:<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Formula:C24H26N6Color and Shape:SolidMolecular weight:398.50CDK2-IN-39
CAS:<p>CDK2-IN-39 (compound 4) is a CDK2 inhibitor.</p>Formula:C14H15N3O4SColor and Shape:SolidMolecular weight:321.352CDK4/9-IN-1
CAS:<p>CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.</p>Formula:C22H34N6O2Color and Shape:SolidMolecular weight:414.544P162-0948
CAS:<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Formula:C20H15FN4O2Color and Shape:SolidMolecular weight:362.357DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Formula:C18H26N4O3SColor and Shape:SoildMolecular weight:378.49CTX-712
CAS:<p>CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.</p>Formula:C19H17FN8O2Color and Shape:SolidMolecular weight:408.39CDK7/12-IN-1
CAS:<p>CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.</p>Formula:C25H34N8OColor and Shape:SolidMolecular weight:462.59Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Formula:C12H8N4O2SColor and Shape:SolidMolecular weight:272.28CDK7-IN-17
CAS:<p>CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.</p>Formula:C24H26F3N6OPColor and Shape:SolidMolecular weight:502.47CDK1-IN-4
<p>CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.</p>Formula:C26H24ClN5SColor and Shape:SolidMolecular weight:474.02PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Formula:C17H18FN5O3Color and Shape:SolidMolecular weight:359.355CDK7-IN-31
CAS:<p>CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.</p>Formula:C27H32F5N6O2PColor and Shape:SolidMolecular weight:598.55Protein kinase inhibitor 11
CAS:<p>Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.</p>Formula:C21H18FN5O2SColor and Shape:SolidMolecular weight:423.463Cdc7-IN-8
CAS:<p>Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)</p>Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40CDK6-IN-1
CAS:<p>CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.</p>Formula:C30H23N5Color and Shape:SolidMolecular weight:453.54Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Formula:C22H15ClFNOColor and Shape:SolidMolecular weight:363.81Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Formula:C14H14N4OSPurity:98.06%Color and Shape:SolidMolecular weight:286.35YKL-1-116
CAS:<p>YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.</p>Formula:C34H38N8O3Purity:98%Color and Shape:SolidMolecular weight:606.72CDK9/PARP-IN-1
CAS:<p>CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.</p>Formula:C38H34F2N8O3Color and Shape:SolidMolecular weight:688.725Protein kinase inhibitor 13
CAS:<p>Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.</p>Formula:C19H20FN5OSColor and Shape:SolidMolecular weight:385.458Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40CDK8-IN-5
CAS:<p>CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.</p>Formula:C26H22N2O4Color and Shape:SolidMolecular weight:426.46CDK4/6-IN-3
CAS:<p>CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.</p>Formula:C25H31FN8Purity:98%Color and Shape:SolidMolecular weight:462.57SGC-CLK-1
CAS:<p>SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.</p>Formula:C19H15F3N6O2Color and Shape:SolidMolecular weight:416.36p38α inhibitor 9
CAS:<p>p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.</p>Formula:C27H24FN3O3Color and Shape:SolidMolecular weight:457.496GFB-12811
CAS:<p>GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.</p>Formula:C22H23F4N5OPurity:98.88%Color and Shape:SolidMolecular weight:449.44LY3143921 hydrate
CAS:<p>LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].</p>Formula:C16H14FN5O2Purity:98.43%Color and Shape:SolidMolecular weight:327.31Tanuxiciclib
CAS:<p>Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.</p>Formula:C15H13FN6OColor and Shape:SolidMolecular weight:312.308GSK-3/CDK5/CDK2-IN-1
CAS:<p>GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].</p>Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.433Tibremciclib
CAS:<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Formula:C28H32F2N8Purity:98%Color and Shape:SolidMolecular weight:518.6YK-2168
CAS:<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Formula:C16H18ClN5Color and Shape:SolidMolecular weight:315.80Ref: TM-T200769
Discontinued product
